Could one year of immunotherapy be enough for advanced melanoma?

NCT ID NCT07376317

Ongoing Disease control Sponsor: Instituto do Cancer do Estado de São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether one year of pembrolizumab (an immunotherapy drug) works as well as the standard two-year course for people with advanced melanoma that cannot be surgically removed. The study involves 29 participants in Brazil's public health system and measures how long the cancer stays under control. If successful, it could mean less time on treatment and lower costs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab (an immunotherapy drug that helps the immune system fight cancer)
What this could lead to: If successful, this could show that a shorter course of immunotherapy is just as effective, reducing treatment burden and costs for patients with advanced melanoma.
What could go wrong: This is a small, early-phase trial with only 29 participants, so results may not apply broadly. There is a risk that one year of treatment is less effective than two years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS MELANOMA MELANOMA METASTATIC MELANOMA RECURRENT STAGE IV MELANOMA

Contacts and locations

Locations

ICESP

São Paulo, São Paulo, 01246000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.